Dr. Ira Kirschenbaum, Chairman Of Orthopaedics at Bronxcare Health System, is a specialist in joint replacement and reconstruction orthopaedics. He is a graduate of the Albert Einstein College of Medicine. Dr. Kirschenbaum is recognized for his design of major joint replacement systems, and he has lectured and published to bring awareness of orthopaedic subjects to the public.
Looking back through history one can see that, even in ancient times, peoples’ bones and joints were somehow set when broken. Orthopaedic medicine has been focused on correcting deformities of bones, muscles and joints. The history of joint replacement can be traced back to the 1890’s when hip joint replacements were offered. In England in the 1960s, the modern technique for total hip replacement was developed, and in the 1970s knee replacement procedures became popular.
Dr. Ira Kirschenbaum recently explained
developments in joint replacement and pointed out that the average age of
people wanting such surgery has decreased somewhat to an average of 65 years.
This may point to obesity as a factor, as well as people wanting to stay more
active as they age. Joint replacement surgeries are less risky today. People
can often go home the same day. But because replacements don’t last forever and
revision surgeries are often needed and more complex, great precision is
required, and results are not as successful as the original replacement.
After joint replacement surgery, Dr. Ira Kirschenbaum is very proactive with his patients, advising them to live healthier lives and emphasizing the dangers of obesity.
More than 50% of patients requiring hip replacements are obese, and this percentage is even higher for those needing knee replacements. Dr. Ira Kirschenbaum emphasizes how important it is to avoid revision surgery when possible.
Read more here https://www.linkedin.com/in/ira-kirschenbaum-5132001a
Eric Lefkofsky has announced that Tempus will collaborate with Feist-Weiller
Cancer Center to take the fight against cancer to the next level. The tech
comppany and the cancer center will work together in performing research
intended to help cancer patients to live better and longer lives. Co-founded by
Eric Lefkofsky, Tempus is a tech company that collects and analyzes clinical data
as well as molecular data.
Tempus focuses on the
analysis of data such as DNA, RNA, as well as proteomic data by conducting
genomic testing. This is in an effort to enable physicians to plan better
treatments for each individual patient. It also organizes radiology scans, lab results, pathology images as well as
clinical notes to enable physicians to have a better understanding on the
clinical context of each case.
Tempus has built a
reputation as a company which is supporting physicians’ efforts to come up with
effective treatment for cancer patients. The data also make examination of
patients in regards to molecular profiles easier as well as determine strong
insights generated by machine-learning algorithms as well as advanced analytics. Eric Lefkofsky has expressed confidence that
Tempus will help cancer patients to not only live longer, but also lead
healthier lives through artificial intelligence.
Tempus has committed to
work with Dr. Maria-Magdalena Georgescu to establish a better understanding of
glioblastoma, metastatic brain disease as well as breast cancer of NLCLC. In
the collaboration, Tempus has been put in-charge of genomic sequencing and
clinical data structuring for patients of Dr. Georgescu. Tempus has always strived to
use machine learning and other capabilities to find patterns that may prove
relevant in regards to how cancer patients respond to therapy.
Center was started in 1997 and it grew to become a large cancer center which
performs research as well as provides training to future cancer care providers.
Feist-Weiller Cancer Center has always been focused on marginalized areas
and underserved communities to make sure cancer patients have access to the
National Cancer Institute clinical research trials.
On the other hand, Tempus
was co-founded by Eric Lefkofsky with one mission in sight: to make relevant
data available and accessible to physicians for effective
administration of treatments
to patients. Since its founding, the company has brought together a team of
experts including bioinformaticians, engineers, scientists, computational
biologists, physicians and more to empower physicians to make not only real-time
decisions, but also data-driven decisions.